Cellectis opens new R&D center in New York; Inovio wins $45M Ebola contract;

@FierceBiotech: One of Shire's top blockbuster drug prospects flops in a key PhII study. News | Follow @FierceBiotech

@JohnCFierce: What bubble? Woodford boosts biotech fund max to $1.2B as investors crowd in. More | Follow @JohnCFierce

@DamianFierce: ICYMI: The thrilling conclusion to #FierceMadness and why I've had "One Shining Moment" stuck in my head all day. Story | Follow @DamianFierce

> Fresh off a $228 million IPO, France's Cellectis has opened up a new, 12,000-square-foot R&D center in Alexandria's big biotech complex on the East Side of Manhattan. "We were convinced by the outstanding potential of New York City, one of the fastest expanding biotech hubs in the world. At the Alexandria Center for Life Science, Cellectis is surrounded by renowned academic and medical institutions, leaders from the commercial life sciences industry, and the world's most robust financial markets," said Dr. André Choulika, founder and CEO of Cellectis. Release

> Inovio Pharmaceuticals ($INO) won a $45 million contract with DARPA to develop new treatments for Ebola. Release

Medical Device News

@FierceMedDev: France's Labco tiptoes closer to IPO. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDiagnostics: Alere earns FDA clearance for rapid diagnostic of Strep A. News | Follow @VarunSaxena2

@EmilyWFierce: Roche nabs EU approval for Avastin for cervical cancer. Report from FiercePharma | Follow @EmilyWFierce

> Aethlon Medical eyes full marketing approval for Ebola biofiltration device. Story

> Synaptive's 'GPS for the brain' gets FDA green light. Article

Pharma News

@FiercePharma: AZ's Onglyza has most to lose at FDA safety confab, analysts say. Story | Follow @FiercePharma

@EricPFierce: Supply chain slip results in expired #Pfizer birth control pills being sold in Canada. More | Follow @EricPFierce

@CarlyHFierce: Mid-cap biotech beats most of the big dogs with 21.9% revenue growth. Article | Follow @CarlyHFierce

> Natco brings its scrappy style to U.S. with Copaxone, Revlimid knockoffs. News

> Vermont governor demands price cut for Amphastar's overdose antidote. Story

CRO News

> WuXi gets a manufacturing subsidiary on the Chinese stock market. Report

> Parexel partners up for clinical trial education. News

> Catalent reaches into Australia with latest buyout. More

> PPD sets off in Japan with SNBL joint venture. Story

> AMRI shutters another plant with an eye on its bottom line. Article

Vaccines News

> GSK relocates vaccine R&D to Maryland with new global center. Story

> Sanofi teams up with VBI Vaccines to improve vaccine stability. News

> Duke University scores $20M from NIH to develop HIV vaccine. Report

> Sanofi 'flipping the model' for high-stakes dengue rollout. More

> Northwest Bio gets $40M more for controversial brain cancer vaccine. Article

Pharma Manufacturing News

> Report: Supply chain efficiency can boost both top- and bottom-line results. Story

> Cipla buying Brazilian distributor for beachhead there. News

> Expired Pfizer contraceptives recalled after supply chain fumble. Report

> Indonesia market expanding but local producers can't keep up. Article

> Chinese drugmaker to build $60M API plant. Story

Pharma Asia News

> Japan, S. Korea hospitals ink clinical pact on regenerative medicine. News

> China's Sihuan marks first U.S. patient enrollment of PhI oncology candidate. Item

> India drug price chief sacked as essential drug prices rise. Article

> U.S. unit of Glenmark settles Medicaid charges for $25M. Story

> Asian device market set to leap to $15B in 2017. Report

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.